JNJ Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Company profile

Alex Gorsky
Fiscal year end
Former names
IRS number

JNJ stock data



22 Feb 21
18 Apr 21
3 Jan 22
Quarter (USD)
Jan 21 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 13.99B 13.99B 13.99B 13.99B 13.99B 13.99B
Cash burn (monthly) 1.66B 276.67M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 5.83B 971.25M n/a n/a n/a n/a
Cash remaining 8.16B 13.01B n/a n/a n/a n/a
Runway (months of cash) 4.9 47.0 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Mar 21 Marillyn A Hewson Deferred Share Units Common Stock Grant Aquire A No No 157.66 210.858 33.24K 3,422.608
9 Mar 21 Weinberger Mark A Deferred Share Units Common Stock Grant Aquire A No No 157.66 210.858 33.24K 3,422.608
9 Mar 21 Washington A. Eugene Deferred Share Units Common Stock Grant Aquire A No No 157.66 345.32 54.44K 24,546.493
12 Feb 21 Robert J Decker Common Stock Payment of exercise Dispose F No No 165.55 261 43.21K 14,215
12 Feb 21 Robert J Decker Common Stock Payment of exercise Dispose F No No 165.55 225 37.25K 14,476
12 Feb 21 Robert J Decker Common Stock Option exercise Aquire M No No 0 655 0 14,701
12 Feb 21 Robert J Decker Common Stock Option exercise Aquire M No No 0 655 0 14,046
12 Feb 21 Robert J Decker Restricted Share Units Common Stock Option exercise Dispose M No No 0 655 0 0
12 Feb 21 Robert J Decker Performance Share Units Common Stock Option exercise Dispose M No No 0 655 0 0
12 Feb 21 Michael H Ullmann Common Stock Payment of exercise Dispose F No No 165.55 5,648 935.03K 151,233.882

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

68.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 3148 2907 +8.3%
Opened positions 359 109 +229.4%
Closed positions 118 117 +0.9%
Increased positions 1408 1344 +4.8%
Reduced positions 1119 1154 -3.0%
13F shares
Current Prev Q Change
Total value 284.79B 267.37B +6.5%
Total shares 1.79B 1.77B +1.4%
Total puts 15.16M 12.99M +16.7%
Total calls 15.76M 11.64M +35.3%
Total put/call ratio 1.0 1.1 -13.8%
Largest owners
Shares Value Change
Vanguard 227.95M $35.87B -0.5%
BLK Blackrock 188.51M $29.67B -2.7%
STT State Street 143.99M $22.66B -3.8%
Geode Capital Management 40.11M $6.3B +1.4%
Wellington Management 35.42M $5.58B +4.9%
State Farm Mutual Automobile Insurance 34.57M $5.44B 0.0%
BAC Bank Of America 32.77M $5.16B -5.1%
NTRS Northern Trust 32.72M $5.15B -2.9%
BK Bank Of New York Mellon 31.96M $5.03B +5.4%
Massachusetts Financial Services 28.27M $4.45B -4.0%
Largest transactions
Shares Bought/sold Change
Norges Bank 27.77M +27.77M NEW
Sanders Capital 6.59M +6.59M NEW
STT State Street 143.99M -5.73M -3.8%
BLK Blackrock 188.51M -5.24M -2.7%
LSV Asset Management 1.89M -1.95M -50.8%
Alliancebernstein 8.48M -1.94M -18.6%
Renaissance Technologies 0 -1.85M EXIT
BAC Bank Of America 32.77M -1.75M -5.1%
Bank Julius Baer & Co. Ltd, Zurich 627.44K -1.74M -73.5%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 3.43M +1.68M +95.7%

Financial report summary

  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • The Company faces significant regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
  • Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
  • Issuer Purchases of Equity Securities
  • Organization and Business Segments
  • Income Before Tax by Segment
  • Financing and Market Risk
  • New Accounting Pronouncements
  • Economic and Market Factors
Content analysis
8th grade Avg
New words: Abtahi, abuse, adherence, adversary, al, American, Amivantamab, App, Appendix, arguing, Arizona, arsenic, atmosphere, Atomic, auction, autoimmune, Azar, Beckerle, bedaquiline, begun, Breast, built, buy, cabotegravir, carbon, career, Carfilzomib, channel, chart, CHF, chromium, CLRA, club, CMF, combat, commensurate, confirmation, constantly, constitutionality, context, conviction, copy, cough, crucial, cultivate, cultivating, deadline, deal, Debtor, Decker, deferral, DEI, deleveraging, dioxide, disability, discomfort, Doudna, downgrade, dropped, duly, Ear, earthquake, Eating, Ebola, eCommerce, ED, EGFR, element, ELMIRON, embedded, ENSEMBLE, Euratom, Exon, expressly, Extra, FASPRO, Fee, feedback, flooding, footprint, forecasted, foresee, foreseeable, formulation, foster, fostering, FTE, fundamental, gas, geopolitical, greenhouse, guided, Healthy, hemorrhagic, Hewson, hexavalent, hurricane, hyaluronidase, Idiopathic, idle, inconsistent, Ingham, Inline, Insertion, instance, interstitial, ischemic, IVOKAMET, jamp, Joly, journey, Jr, Juvenile, LCC, learned, learning, Linkbase, macroeconomic, Madison, Mallinckrodt, McClellan, mediation, mental, Mentor, migration, mind, Mo, Momenta, Monthly, Moody, motivate, Movement, Mulcahy, MVABEA, Nippon, NonQualified, Nose, Notwithstanding, object, objected, objective, Orange, outbreak, page, pain, pandemic, partnership, path, PBO, peer, persistence, personnel, philosophy, PHS, physical, Polyarticular, Polymorph, population, postponed, preclinical, predominantly, Prince, proactively, profile, prolonged, PROPLAN, Proponent, published, reassign, recoup, recovery, refine, Reg, reinforce, remind, renewed, reopen, repression, rescheduled, resurgence, retinal, robust, satisfactory, scale, scarcity, Schema, shape, Shinyaku, SIRTURO, site, situation, skill, skilled, skin, SKU, smooth, soliciting, speed, SPRAVATO, Squibb, strict, strike, substitute, succeed, SURGIFLO, Survey, Taxonomy, TCA, teaching, testimony, thereto, thereunto, Throat, top, tornado, tribal, TRINZA, TruMatch, turnover, unanimously, Underpinning, undersigned, uninterrupted, unique, unsecured, unsuccessful, upward, usage, vaccine, valuable, VGYAAN, wage, water, Weinberger, welfare, wildfire, workplace, wrongful, XBRL, ZABDENO
Removed: Abbott, ACCOUNTANT, admitted, adult, affirmance, ago, Amerigen, Amneal, amounting, antibody, Argentum, articulated, assert, attractive, auditing, Aurobindo, Belgian, Bio, biosurgery, biosurgical, bound, Breckenridge, catheter, ceased, Celltrion, Citron, CJEU, Codman, commence, COMPEED, complementary, consummated, counterclaimed, covenant, Covidien, CYPHER, declaratory, dedicated, denying, disclosing, discontinuation, discretion, dysfunction, efficient, electrosurgical, endocutter, endomechanical, English, ENSEAL, failed, franc, FZE, gastroesophageal, generation, geometry, gland, Glenmark, guaranteed, half, Hetero, Hexal, Hikma, Hospira, HRA, HyClone, Indoco, ineligible, infringed, insulin, Integra, interim, InvaGen, issuing, Jaw, JSI, Kabi, launched, leasing, LEVAQUIN, LINX, manner, Medinol, Megadyne, meibomian, Micro, MINE, modified, moot, nature, necessarily, negotiated, Neuravi, neurointerventional, Neurosurgery, noninfringement, original, payout, perspective, precedent, prime, Prinston, prospective, provisionally, pump, reclassification, rental, resistant, retrospectively, revoked, sa, SAB, Sealer, Searle, SELECT, Sensing, serve, shareholding, shelf, Shilpa, Sightbox, Sigmapharm, SMARTTOUCH, solution, SPC, spun, stranded, sublicensee, subscription, sue, Sun, supplementary, Taro, TearScience, tender, THERMOCOOL, threatened, tissue, topic, Torax, Torrent, transplant, treating, UC, unapproved, unaudited, unreasonably, untreated, vacate, whistleblower, willfully, Wockhardt